Skip to main content


Firm News

Mayer Brown advises Oxford BioDynamics on its admission to AIM

1 December 2016

London — Mayer Brown has advised new client Oxford BioDynamics Plc (“OBD”), an Oxford University spin-out, on its admission to AIM with an expected market capitalization of £136 million.

OBD is a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. OBD’s proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

OBD will use the proceeds raised from listing on AIM to accelerate its growth strategy for its EpiSwitch™ technology. Admission to trading on AIM is expected to take place on 6 December 2016.

The Mayer Brown team was led by Corporate & Securities partner Robert Hamill and included Corporate & Securities senior associate Rebecca Bothamley and associate Harriet Hainsworth; IP partner Mark Prinsley and associate Daniel Gallagher; and Employment & Benefits consultant Andrew Stanger, and senior associates Elizabeth Hodgkinson and Nicola Thomson.

Media Contact

  • Helen Obi
    Senior Corporate Communications & PR Manager
    T +44 20 3130 8527
  • Katie Tibbitts
    Senior PR Executive
    T +44 20 3130 8120

Related Information

  • Related People
    Robert Hamill
    T +44 20 3130 3558
    Rebecca Bothamley
    T +44 20 3130 3681
    Harriet Hainsworth
    T +44 20 3130 3604
    Mark A. Prinsley
    T +44 20 3130 3900
    Daniel Gallagher
    T +44 20 3130 3537
    Andrew Stanger
    Legal Professional / Consultant
    T +44 20 3130 3934
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.